A Phase 2 interventional study of brentuximab vedotin in Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic and Lymphoma, Non-Hodgkin, sponsored by Seagen Inc.. Completed at 17 sites in 2 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2017-02-02.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 18th largest by enrollment, is one of 3 that started in 2009, is one of 41 in phase 2, and was the 4th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 7th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 2, and was the 6th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
This is a multicenter, open-label study to evaluate single-agent brentuximab vedotin (SGN-35) treatment in patients who previously participated in a brentuximab vedotin study, including Studies SGN35-005 (NCT01100502), SGN35-007 (NCT01026233), and SGN35-008 (NCT01026415). Patients treated on this study (SGN35-006) could re-enroll on study if eligible. The study consisted of 2 arms, as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrew consent to participate in any prior brentuximab vedotin study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
Drug: brentuximab vedotin
Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
Drug: brentuximab vedotin
Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
Also known as: Adcetris
Objective Response Rate by Investigator
Percentage of participants in the retreatment arm who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
Time frame: Up to approximately 38 months
Adverse Events by Severity, Seriousness, and Relationship to Treatment
Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on SGN35-006). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
Time frame: up to 39 months
Laboratory Abnormalities >/= Grade 3
Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
Time frame: Up to 39 months
Duration of Objective Response by Kaplan-Meier Analysis
Duration of objective response (CR + PR) on retreatment, defined as time of initial response until disease progression or death
Time frame: Up to 38 months
Progression-free Survival by Kaplan-Meier Analysis
Progression-free survival, defined as time from start of study treatment in the retreatment arm to disease progression per investigator or death due to any cause
Time frame: Up to approximately 29 months
Overall Survival
Overall survival for both extension and retreatment arms, defined as time from start of study treatment to date of death due to any cause
Time frame: Up to approximately 41 months
Incidence of Antitherapeutic Antibodies
Counts of participants with anti-brentuximab vedotin antibodies at any time during extension treatment on Study SGN35-006 or number of retreatment experiences with anti-brentuximab vedotin antibodies at any time during retreatment
Time frame: Up to 39 months
Jul 2009 - Mar 2013
| Milestone | BV Extension | BV Retreatment |
|---|---|---|
| Started | 78 | 32 |
| Completed | 0 | 0 |
| Not completed | 78 | 32 |
| Withdrew: Progressive disease | 33 | 12 |
| Withdrew: Adverse event | 15 | 9 |
| Withdrew: Physician decision | 14 | 6 |
| Withdrew: Study stopped by sponsor | 4 | 4 |
| Withdrew: Withdrawal by subject | 12 | 1 |
| Milestone | BV Extension | BV Retreatment |
|---|---|---|
| Started | 78 | 32 |
| Completed | 27 | 9 |
| Not completed | 51 | 23 |
| Withdrew: Study stopped by sponsor | 40 | 20 |
| Withdrew: Re-enrolled for retreatment | 2 | 3 |
| Withdrew: Lost to follow-up | 7 | 0 |
| Withdrew: Patient unavailable for site visits | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
Percentage of participants in the retreatment arm who achieved a best response of complete remission (CR, disappearance of all evidence of disease) or partial remission (PR, regression of greater than or equal to 50% of measurable disease and no new sites) per Cheson 2007 Revised Response Criteria for Malignant Lymphoma.
| percentage of retreatment experiences | BV Retreatment - HL | BV Retreatment - ALCL | BV Retreatment - Other | BV Retreatment Total |
|---|---|---|---|---|
| Objective Response Rate by Investigator | 60 (36.1 to 80.9) | 91 (58.7 to 99.8) | 33 (0.8 to 90.6) | 68 (49.5 to 82.6) |
Counts of participants who had adverse events or treatment-emergent adverse events (TEAE, defined as newly occurring or worsening after first dose on SGN35-006). Serious adverse events are reported from the time of informed consent. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) were used to assess severity (1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death). Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an adverse event within a category are counted once within the category.
| participants | BV Extension | BV Retreatment |
|---|---|---|
| Any TEAE | 75 | 31 |
| TEAE related to study drug | 65 | 27 |
| TEAE with severity grade >/=3 | 37 | 16 |
| Discontinued treatment due to adverse event | 13 | 9 |
| Serious adverse event | 16 | 9 |
| Serious adverse event related to study drug | 10 | 4 |
Counts of study participants with post-baseline laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
| participants | BV Extension | BV Retreatment |
|---|---|---|
| Any >/= Grade 3 laboratory abnormality | 29 | 12 |
| Lymphocytes (low) | 16 | 8 |
| Leukocytes (low) | 3 | 3 |
| Neutrophils (low) | 7 | 3 |
| Phosphate (low) | 7 | 3 |
| Platelets (low) | 4 | 3 |
| Aspartate aminotransferase (high) | 1 | 2 |
| Glucose (high) | 3 | 2 |
| Alanine aminotransferase (high) | 1 | 1 |
| Bilirubin (high) | 0 | 1 |
| Calcium (low) | 0 | 1 |
| Hemoglobin (low) | 1 | 1 |
| Potassium (low) | 0 | 1 |
| Sodium (low) | 2 | 0 |
Duration of objective response (CR + PR) on retreatment, defined as time of initial response until disease progression or death
| months | BV Retreatment - HL | BV Retreatment - ALCL | BV Retreatment - Other | BV Retreatment Total |
|---|---|---|---|---|
| Duration of Objective Response by Kaplan-Meier Analysis | 9.2 (2.1 to NA) | 8.8 (1.4 to 12.9) | NA (NA to NA) | 9.2 (6.6 to 12.9) |
Progression-free survival, defined as time from start of study treatment in the retreatment arm to disease progression per investigator or death due to any cause
| months | BV Retreatment - HL | BV Retreatment - ALCL | BV Retreatment - Other | BV Retreatment Total |
|---|---|---|---|---|
| Progression-free Survival by Kaplan-Meier Analysis | 9.9 (3.4 to 13.4) | 12.9 (3.4 to 18.5) | 4.4 (1.2 to NA) | 9.9 (4.4 to 13.4) |
Overall survival for both extension and retreatment arms, defined as time from start of study treatment to date of death due to any cause
| months | BV Extension Total | BV Retreatment - HL | BV Retreatment - ALCL | BV Retreatment - Other | BV Retreatment Total |
|---|---|---|---|---|---|
| Overall Survival | NA (32.1 to NA) | NA (11.4 to NA) | NA (NA to NA) | NA (5.1 to NA) | NA (19.5 to NA) |
Counts of participants with anti-brentuximab vedotin antibodies at any time during extension treatment on Study SGN35-006 or number of retreatment experiences with anti-brentuximab vedotin antibodies at any time during retreatment
| participants or experiences | BV Extension | BV Retreatment |
|---|---|---|
| Incidence of Antitherapeutic Antibodies | 15 | 12 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BV Extension | — | 16/78 (20.5%) | 75/78 (96.2%) |
| BV Retreatment | — | 9/32 (28.1%) | 31/32 (96.9%) |
| Event | BV Extension | BV Retreatment |
|---|---|---|
| PneumoniaInfections and infestations | 3/78 | 2/32 |
| DehydrationMetabolism and nutrition disorders | 0/78 | 2/32 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/78 | 2/32 |
| Peripheral sensory neuropathyNervous system disorders | 0/78 | 2/32 |
| Mental status changesPsychiatric disorders | 1/78 | 2/32 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/78 | 1/32 |
| LeukocytosisBlood and lymphatic system disorders | 0/78 | 1/32 |
| MethaemoglobinaemiaBlood and lymphatic system disorders | 0/78 | 1/32 |
| Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders | 0/78 | 1/32 |
| GlaucomaEye disorders | 0/78 | 1/32 |
| Event | BV Extension | BV Retreatment |
|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 36/78 | 17/32 |
| DiarrhoeaGastrointestinal disorders | 15/78 | 12/32 |
| NauseaGastrointestinal disorders | 19/78 | 12/32 |
| FatigueGeneral disorders | 23/78 | 11/32 |
| Upper respiratory tract infectionInfections and infestations | 25/78 | 6/32 |
| HeadacheNervous system disorders | 10/78 | 9/32 |
| PyrexiaGeneral disorders | 20/78 | 8/32 |
| Peripheral motor neuropathyNervous system disorders | 4/78 | 8/32 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 7/78 | 8/32 |
| AnaemiaBlood and lymphatic system disorders | 7/78 | 7/32 |
All participants who received treatment
| Age, Customized(years) | BV Extension | BV Retreatment | Total |
|---|---|---|---|
| Median | 32 (15 to 78) | 37 (16 to 72) | 33.5 (15 to 78) |
| Gender(Participants) | BV Extension | BV Retreatment | Total |
|---|---|---|---|
| Female | 35 | 17 | 52 |
| Male | 43 | 15 | 58 |
| Race (NIH/OMB)(Participants) | BV Extension | BV Retreatment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 7 | 4 | 11 |
| White | 66 | 27 | 93 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | BV Extension | BV Retreatment | Total |
|---|---|---|---|
| France | 0 | 3 | 3 |
| United States | 78 | 29 | 107 |
| Eastern Cooperative Oncology Group Performance Status(participants) | BV Extension | BV Retreatment | Total |
|---|---|---|---|
| 0 | 47 | 12 | 59 |
| 1 | 30 | 18 | 48 |
| 2 | 0 | 2 | 2 |
| 3-5 | 0 | 0 | 0 |
| Missing | 1 | 0 | 1 |
| Disease diagnosis(participants) | BV Extension | BV Retreatment | Total |
|---|---|---|---|
| Hodgkin lymphoma (HL) | 68 | 21 | 89 |
| Systemic anaplastic large cell lymphoma (ALCL) | 8 | 8 | 16 |
| Other | 2 | 3 | 5 |
The record gives a start of Jul 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin